X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
egfr blockade (2) 2
index medicus (2) 2
oncology (2) 2
resistance (2) 2
acquired-resistance (1) 1
adenocarcinoma - diagnostic imaging (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - secondary (1) 1
amplification (1) 1
analysis (1) 1
animals (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
breast-cancer (1) 1
cancer (1) 1
cell biology (1) 1
class i phosphatidylinositol 3-kinases - genetics (1) 1
clinical decision-making (1) 1
clonal evolution (1) 1
colon-cancer (1) 1
colorectal cancer (1) 1
colorectal neoplasms - diagnostic imaging (1) 1
colorectal neoplasms - drug therapy (1) 1
colorectal neoplasms - genetics (1) 1
colorectal neoplasms - pathology (1) 1
consensus molecular subtypes (1) 1
ctdna (1) 1
disease progression (1) 1
dna mutational analysis (1) 1
drug resistance, neoplasm - genetics (1) 1
drug-sensitivity (1) 1
female (1) 1
gene (1) 1
gene amplification (1) 1
genetic aspects (1) 1
genetic research (1) 1
her2 amplification (1) 1
heterogeneity (1) 1
humans (1) 1
in-vitro (1) 1
inhibition (1) 1
italy (1) 1
lapatinib (1) 1
lapatinib - administration & dosage (1) 1
lapatinib - adverse effects (1) 1
liquid biopsy (1) 1
liver neoplasms - diagnostic imaging (1) 1
liver neoplasms - drug therapy (1) 1
liver neoplasms - genetics (1) 1
liver neoplasms - secondary (1) 1
magnetic resonance imaging (1) 1
male (1) 1
metastasis (1) 1
mice, inbred nod (1) 1
mice, scid (1) 1
mice, transgenic (1) 1
models (1) 1
pathological complete response (1) 1
pik3ca mutations (1) 1
precision medicine (1) 1
predictive value of tests (1) 1
progression-free survival (1) 1
protein kinase inhibitors - administration & dosage (1) 1
protein kinase inhibitors - adverse effects (1) 1
rapid autopsy (1) 1
ras proteins - genetics (1) 1
receptor, erbb-2 - antagonists & inhibitors (1) 1
receptor, erbb-2 - genetics (1) 1
risk factors (1) 1
signal transduction - drug effects (1) 1
solid tumors (1) 1
targeted therapy (1) 1
therapy (1) 1
time factors (1) 1
tomography, x-ray computed (1) 1
trastuzumab (1) 1
trastuzumab - administration & dosage (1) 1
trastuzumab - adverse effects (1) 1
treatment outcome (1) 1
tumor cells, cultured (1) 1
tumor heterogeneity (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Cell, ISSN 1535-6108, 07/2018, Volume 34, Issue 1, pp. 148 - 162.e7
Targeting HER2 is effective in 24% of amplified metastatic colorectal cancer; however, secondary resistance occurs in most of the cases. We studied the... 
trastuzumab | targeted therapy | rapid autopsy | colorectal cancer | clonal evolution | HER2 amplification | lapatinib | liquid biopsy | ctDNA | resistance | BREAST-CANCER | HETEROGENEITY | PIK3CA MUTATIONS | THERAPY | AMPLIFICATION | SOLID TUMORS | GENE | ONCOLOGY | ACQUIRED-RESISTANCE | EGFR BLOCKADE | PATHOLOGICAL COMPLETE RESPONSE | CELL BIOLOGY | Predictive Value of Tests | ras Proteins - genetics | Liquid Biopsy | Class I Phosphatidylinositol 3-Kinases - genetics | Receptor, ErbB-2 - genetics | Colorectal Neoplasms - genetics | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Tomography, X-Ray Computed | Protein Kinase Inhibitors - adverse effects | Time Factors | DNA Mutational Analysis | Clinical Decision-Making | Colorectal Neoplasms - drug therapy | Female | Adenocarcinoma - genetics | Receptor, ErbB-2 - antagonists & inhibitors | Tumor Cells, Cultured | Liver Neoplasms - secondary | Lapatinib - adverse effects | Liver Neoplasms - genetics | Risk Factors | Liver Neoplasms - drug therapy | Trastuzumab - adverse effects | Mice, Transgenic | Treatment Outcome | Colorectal Neoplasms - diagnostic imaging | Trastuzumab - administration & dosage | Mice, SCID | Adenocarcinoma - drug therapy | Liver Neoplasms - diagnostic imaging | Adenocarcinoma - secondary | Disease Progression | Magnetic Resonance Imaging | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Animals | Gene Amplification | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Progression-Free Survival | Italy | Mice, Inbred NOD | Adenocarcinoma - diagnostic imaging | Colorectal Neoplasms - pathology | Lapatinib - administration & dosage | Genetic research | Genetic aspects | Metastasis | Analysis | Colorectal cancer | Cancer
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 10/2019, Volume 25, Issue 20, pp. 6243 - 6259
Purpose: Patient-derived xenograft (PDX) models accurately recapitulate the tumor of origin in terms of histopathology, genomic landscape, and therapeutic... 
COLON-CANCER | DRUG-SENSITIVITY | IN-VITRO | INHIBITION | MODELS | ONCOLOGY | CONSENSUS MOLECULAR SUBTYPES | RESISTANCE | PRECISION MEDICINE | EGFR BLOCKADE | TUMOR HETEROGENEITY
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.